



Vehicles

SyrSpend[®] SF Alka

Powder for reconstruction

www.fagron.com

 **Fagron**
personalizing
medicine

SyrSpend® SF Alka

Powder for reconstruction


Superior suspending technology

SyrSpend® SF is an innovative vehicle range for the compounding of oral liquid dosage forms. Based on food starch, SyrSpend® SF's superior suspending properties provide consistent, individual dosing throughout treatment.¹⁻³

The excellent compatibility with a broad range of APIs and meticulous ingredient safety make SyrSpend® SF highly suitable for compounding safe and stable customized medication.

- Innovative and highly stable suspensions base
- Compatibility with a broad range of acid-labile APIs
- Formulated using only safe and well-tolerated ingredients
- Optimal palatability and taste-masking properties for improved compliance

Compounding a palatable omeprazole suspension in minutes




SyrSpend® SF Alka offers a safe and convenient solution for compounding oral liquid dosage forms with acid-labile active pharmaceutical ingredients (APIs).

- Premeasured powder in a dispensing container to make 100 ml or 200 ml suspensions
- Buffered to pH >7 for acid-labile APIs
- Allows for easy compounding in the dispensing container
- Proven chemical, physical, and microbiological stability with omeprazole for 60 days.^{4,5}
- Accuracy and consistency in dosing due to the starch-based active suspending technology
- Easy to swallow and taste-masking with a pleasant, sweet taste
- Free of sugar, alcohol, colorants, parabens, preservatives, or other harmful or controversial ingredients


SyrSpend® SF Alka

Powder for reconstruction

Efficient solutions for every situation⁹



Efficient solutions for every situation



References

1. Visser JC et al. Comparison of Rheological and Sedimentation Behavior of Commercially Available Suspending Vehicles for Oral Pharmaceutical Preparations. *International Journal of Pharmaceutical Compounding*;22(3):247-251.
2. Dijkers, E, Nanhekhan V, Thorissen V and Hudson P. Suspensions as a Valuable Alternative to Extemporaneously Compounded Capsules. *International journal of pharmaceutical compounding* 21 2 (2017): 171-175.
3. Dijkers ECF, Polonini H and Ferreira A. Content Uniformity of Extemporaneous Compounded Suspensions. Abstract accepted for the EAHP 2020 congress Hospital Pharmacy 5.0 - the future of patient care.
4. Whaley PA, Voudrie MA, Sorenson B. Stability of omeprazole in SyrSpend SF Alka (reconstituted). *International Journal of Pharmaceutical Compounding*. 2012;16(2):164-6.
5. Polonini HC, Silva SL, Loures S, Almy R, Balland A, Brandão MAF and Ferreira AO. Compatibility of proton pump inhibitors in a preservative-free suspending vehicle. *Eur J Hosp Pharm* 2016;0:1-7.
6. Polonini HC, Silva SL, Loures S, Almy R, Balland A, Brandão MAF and Ferreira AO. Compatibility of proton pump inhibitors in a preservative-free suspending vehicle. *Eur J Hosp Pharm* 2016;0:1-7.